REN and Hepatic fibrosis: Recently, also some direct renin inhibitors (e.g., aliskiren) that inhibit the formation of angiotensin I from angiotensinogen were successfully tested in rodent models of hepatic injury (Lee et al., 2013) suggesting that the renin-angiotensin system offer many potential therapeutically beneficial drug targets for interfering with hepatic fibrosis.